Celcuity Inc. announced the publication of non-clinical data in the journal Cancers, highlighting the efficacy of its lead drug candidate, gedatolisib, in gynecologic cancer models. The study, published on October 17, 2024, demonstrated gedatolisib's superior growth-inhibitory effects compared to single-node PI3K/AKT/mTOR (PAM) inhibitors.
The research indicated that gedatolisib, a pan-PI3K/mTOR inhibitor, exerted greater growth-inhibitory effects in almost all tested endometrial, ovarian, and cervical cancer cell lines, regardless of PAM pathway mutations. This suggests a broad applicability of its comprehensive pathway blockade.
Furthermore, the study showed that gedatolisib, when combined with either fulvestrant or palbociclib, inhibited tumor growth in endometrial and ovarian cancer xenograft models. These non-clinical findings provide support for the development of gedatolisib in combination with hormonal therapy and/or cell cycle inhibitors for gynecologic cancer treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.